Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

EXPLAINED: Compounded glp 1s and competition force novo nordisk to slash outlook | Rare Historical Photos

Valparaiso,,In,Usa,December,13,,2023:,Ozempic,Pen,And,Box

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Sales increased by 13% in Danish kroner and 18% at CER, driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 8% to 38.37 billion Danish kroner, and Obesity care sales increased by 53% to 20.37 billion Danish kroner.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.